Open an account

Novartis AG

NVS · SWISS

$151.12−$5.15 (−3.30%)TodayMarket closed ·
Prev close $156.27

About NVS

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 75,267 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Employees
75,267
Headquarters
Basel, Basel-Stadt
Listed
May 7, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
novartis.com

NVS key statistics

Market cap
235.92B
Price-earnings ratio
23.57
Dividend yield
3.17%
Average volume
1.75M
Volume
4.36M
Open price
$155.97
High today
$156.08
Low today
$149.17
52 Week high
$170.46
52 Week low
$121.57

Novartis AG (NVS) at a glance

Novartis AG (NVS) last traded at $151.12, with a market cap of 235.92B, a price-to-earnings ratio of 23.57 and a dividend yield of 3.17%.

Today the stock has traded between $149.17 and $156.08. The current price is 1.3% above the day's low and 3.2% below its high.

Volume so far is 4.36M shares, above the average of 1.75M shares a day.

Over the past year Novartis AG has ranged from $121.57 to $170.46, and now sits 60% of the way up that range.

Novartis AG met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported $2.41 per share against an estimate of $2.31.

The average analyst price target is $155.66, 3.0% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

40%of 5 analyst ratings say Buy
  • Buy40.0%
  • Hold60.0%
  • Sell0.0%
Price target · 26 analystsAvg $155.66
Low
$121.31
Now
$151.12
High
$191.08

NVS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 4.3% on average.

  1. Q3 FY24: reported $2.06 per share against an estimate of $1.99
  2. Q4 FY24: reported $1.98 per share against an estimate of $1.87
  3. Q1 FY25: reported $2.28 per share against an estimate of $2.14
  4. Q2 FY25: reported $2.42 per share against an estimate of $2.41
  5. Q3 FY25: reported $2.25 per share against an estimate of $2.30
  6. Q4 FY25: reported $2.03 per share against an estimate of $2.03
  7. Q1 FY26: reported $1.99 per share against an estimate of $2.18
  8. Q2 FY26: reported $2.41 per share against an estimate of $2.31

NVS news

  • Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis

  • Novartis Announces Its Data From Phase III NATALEE Study Demonstrates Kisqali Eliminates Risk Of Death By ~20% In Patients With Stage II And III HR+/Her2- Early Breast Cancer

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • Vandana Singh

    FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives

  • Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.